Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

7 Short-Term Stocks to Make a Move on Now

By Josh Enomoto, InvestorPlace Contributor

For investors that are short on time and want to make profits now, these short-term stocks to buy could deliver the goods.

Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data

By Josh Enomoto, InvestorPlace Contributor

Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock.

Why Is Disney (DIS) Stock Trending Today?

By Josh Enomoto, InvestorPlace Contributor

Although Disney is under pressure due to the disappointing debut of the Avatar sequel, patience may be key for DIS stock.

The 7 Best Tech Stocks to Buy Now

By Josh Enomoto, InvestorPlace Contributor

Those who can stomach continued volatility may want to start placing bets on the best tech stocks to buy now.

Why Is Soleno Therapeutics (SLNO) Stock Up 130% Today?

By Josh Enomoto, InvestorPlace Contributor

With Soleno Therapeutics receiving a financial commitment, SLNO stock skyrocketed. Still, prospective investors should be careful.

Load More